Semaglutide (GLP-1) targets appetite control and metabolic benefits, while Tirzepatide offers enhanced results through its dual GLP-1 + GIP action
This aligns with the biology: repeated stimulation of the wound healing cascade and growth factor release compounds over time
Another proof of this was that motor fluctuations in PD patients improved after SIBO eradication, hence providing more support of the association between SIBO and motor fluctuations (Lubomski et al., 2020)
BPC-157 shows remarkable stability and can be administered orally with some retained activity, unlike most peptides which degrade in the digestive system
Phase 3 monotherapy results A post-hoc analysis of the phase 3 data showed cagrilintide 2.4 mg monotherapy produced 11.8% average body weight reduction versus 2.3% for placebo over 68 weeks
Choe SA, Kim S, Im C, et al